The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Yang, Qin; Wang, Jie; Zhong, Pingyong; Mou, Tinggang; Hua, Hao; Liu, Pan; Xie, Fei

doi:10.1186/s12935-020-1148-8

Cited by 14 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MIR31HG is a novel factor involved in melanoma progression ( 31 ). Increased expression of FAM83H-AS1 may predict poor prognosis in cancer patients ( 32 ). In this study, HCG11 was positively correlated with advanced stage and lymph node metastasis and negatively associated with NPC patient survival.…”

Section: Discussionmentioning

confidence: 99%

LncRNA HCG11 Facilitates Nasopharyngeal Carcinoma Progression Through Regulating miRNA-490-3p/MAP3K9 Axis

et al. 2022

View full text Add to dashboard Cite

PurposeLong noncoding RNAs (LncRNAs) play complex but important roles in the progression of various tumors. This study aimed to elucidate the functional mechanisms of the HLA complex group 11 (HCG11) in nasopharyngeal carcinoma (NPC).Patients and MethodsHCG11 levels in NPC specimens were determined by fluorescence in situ hybridization (FISH) and qPCR. Proliferation, apoptosis, and metastasis of NPC cells were determined using CCK8, colony formation, annexin V-PI, and transwell assays. A murine tumor xenograft model was used to investigate the regulatory function of HCG11 in NPC in vivo, and immunohistochemical staining was used to determine the Ki-67 level in tumors. The target relationships between HCG11, microRNA miR-490-3p, and MAPK kinase kinase 9 (MAP3K9) were detected using bioinformatics, qPCR, western blotting, and luciferase reporter assays.ResultsHCG11 was highly expressed in NPC tissues and was positively associated with tumor stage, lymphatic metastasis, and poor prognosis. Functionally, HCG11 knockdown inhibited proliferation and migration and induced apoptosis of NPC cells. Mechanistically, miR-490-3p is a direct target of HCG11, oncogenic functions of HCG11 in NPC cell proliferation and migration can be partially reversed by the miR-490-3p inhibitor. HCG11 significantly increased mitogen-activated protein kinase MAPK kinase 9 (MAP3K9) levels by inhibiting miR-490-3p.ConclusionHCG11 facilitates NPC progression via MAP3K9 signaling by sponging miRNA-490-3p, which may contribute to new prognostic markers and promising therapeutic targets.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA HCG11 Facilitates Nasopharyngeal Carcinoma Progression Through Regulating miRNA-490-3p/MAP3K9 Axis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recently, plenty of studies indicated that several lncRNAs may serve as a promising prognostic biomarker for cancer patients, such as SNHG1 [32], linc00152 [33], PCAT-1 [34], FAM83H-AS1 [35] and so on. And ZFAS1 is exactly one of them.…”

Section: Discussionmentioning

confidence: 99%

Clinical value of lncRNA ZFAS1 in various cancers: an updated meta-analysis of 2263 cancer patients

Liu

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: LncRNA ZNFX1 antisense RNA 1 (ZFAS1) is largely reported to be abnormally expressed in various human cancers and associated with unfavorable prognosis. So this study aims to further investigate its clinical value in multifarious cancers.Methods: Databases of PubMed, Web of science, Cochrane library, Embase, Chinese National Knowledge Infrastructure and Wanfang was retrieved to collect eligible studies until October 22, 2020. The clinical role of ZFAS1 was comprehensively assessed by STATA 12.0. Additionally, the CeRNA network in which ZFAS1 involved was constructed. And function analysis of targeted mRNAs was performed by R package “cluster profiler”.Results: 23 studies of 2263 cancer patients met the inclusion criteria in this meta-analysis. The comprehensive results suggested that patients with elevated ZFAS1 expression got poor overall survival (OS) (HR=1.80, 95%CI: 1.50-2.10, P≤0.001), and they are prone to lymph node metastasis (OR=2.67, 95%CI: 1.73-4.14, P≤0.001), distant metastasis (DM) (OR=3.45, 95%CI: 1.61-7.39, P=0.001), advanced TNM stage (HTS) (OR=2.99, 95%CI: 1.97-4.54, P≤0.001), larger tumor size (LTS) (OR=1.54, 95%CI: 1.05-2.24, P≤0.001), poor histologic grade (PHG) (OR=1.57, 95%CI: 1.09-2.26, P=0.015). The CeRNA network and function analysis revealed the potential mechanism which ZFAS1 may involve in cancers.Conclusion: The current analysis revealed that elevated ZFAS1 expression is common in various cancer and was significantly associated with poor OS and clinical characteristics, thus it may function as prognostic biomarker in various cancer. Nevertheless, larger well-designed clinical research a is still warranted to verify our findings.

show abstract

“…However, the diversified results, the heterogeneity of lncRNAs biology and prognosis, as well as the presence of different treatment options make the clinical decision-making process highly varied. Thus, a series of systematic reviews and meta-analyses have been conducted to provide further evidences on the relationship between variants of dysregulated lncRNAs and prognosis of cancer ( Chen C et al, 2018 ; Quan et al, 2018 ; Tian et al, 2018 ; Zhang S et al, 2020 ; Yang et al, 2020 ; Zhou et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Background: There is growing evidence that a number of lncRNAs are involved in the pathogenesis of non-small-cell lung cancer (NSCLC). However, studies on lncRNA expression in NSCLC patients are far from conclusive. Therefore, we performed a systematic review of such studies to collect and examine the evidence on the potential role of lncRNAs in the development of NSCLC.Methods: We systematically searched seven literature databases to identify all published studies that evaluated the expression of one or more lncRNAs in human samples with NSCLC (cases) and without NSCLC (controls) from January 1, 1995 to May 24, 2021. Quality assessment of studies was conducted by using the “Quality in Prognosis Studies” (QUIPS) tool, and the heterogeneity across studies was analyzed with the I-squared statistic and chi-square-based Q-tests. Either fixed or random-effect meta-analysis was performed to summarize effect size to investigate the association between lncRNA expression and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and clinicopathological features. The R statistical software program was used to conduct standard meta-analysis.Results: We finally obtained 48 studies with 5,211 patients included in this review after screening. Among the 48 lncRNAs, 38 lncRNAs were consistently upregulated, and 10 were deregulated in patients with NSCLC compared with the control groups. The upregulated lncRNAs were positively associated with histological type: study number (n) = 18, odds ratio (OR) = 0.78, 95% CI: 0.65–0.95 and OR = 1.30, 95% CI: 1.08–1.57, p < 0.01; TNM stages: n = 20, OR = 0.41, 95% CI: 0.29–0.57 and OR = 2.44, 95% CI: 1.73–3.44, p < 0.01; lymph node metastasis: n = 29, OR = 0.49, 95% CI: 0.34–0.71 and OR = 2.04, 95% CI: 1.40–2.96, p < 0.01; differentiation grade: n = 6, OR = 0.61, 95% CI: 0.38–0.99 and OR = 1.63, 95% CI: 1.01–2.64, p < 0.01; distant metastasis: n = 9, OR = 0.37, 95% CI: 0.26–0.53 and OR = 2.72, 95% CI: 1.90–3.90, p < 0.01; tumor size: n = 16, OR = 0.52, 95% CI: 0.43–0.64 and OR = 1.92, 95% CI: 1.57–2.34, p < 0.01; and overall survival [n = 38, hazard ratio (HR) = 1.79, 95% CI = 1.59–2.02, p < 0.01]. Especially, five upregulated lncRNAs (linc01234, ZEB1-AS1, linc00152, PVT1, and BANCR) were closely associated with TNM Ⅲa stage (n = 5, OR = 4.07, 95% CI: 2.63–6.28, p < 0.01). However, 10 deregulated lncRNAs were not significantly associated with the pathogenesis and overall survival in NSCLC in the meta-analysis (p ≥ 0.05).Conclusion: This systematic review suggests that the upregulated lncRNAs could serve as biomarkers for predicting promising prognosis of NSCLC. The prognostic value of downregulated lncRNA in NSCLC needs to be further explored.Systematic Review Registration: (http://www.crd.york.ac.uk/PROSPERO).identifier CRD42021240635.

show abstract

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Cited by 14 publications

References 33 publications

LncRNA HCG11 Facilitates Nasopharyngeal Carcinoma Progression Through Regulating miRNA-490-3p/MAP3K9 Axis

LncRNA HCG11 Facilitates Nasopharyngeal Carcinoma Progression Through Regulating miRNA-490-3p/MAP3K9 Axis

Clinical value of lncRNA ZFAS1 in various cancers: an updated meta-analysis of 2263 cancer patients

The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About